BUCHANG PHARMA(SH:603858) Shang Hai Zheng Quan Bao·2025-04-09 19:17Core Viewpoint - The announcement details the changes in the business scope of the wholly-owned subsidiaries of Shandong Buchang Pharmaceutical Co., Ltd., specifically Baoding Tianhao Pharmaceutical Co., Ltd. and Shaanxi Buchang Pharmaceutical Co., Ltd., aimed at improving operational management [1][5]. Group 1: Business Scope Changes - Baoding Tianhao's previous business scope included the production of various pharmaceutical forms, while the new scope allows for broader technical services and drug production [1][2]. - Shaanxi Buchang's business scope has also been expanded to include additional services such as solar energy technology services and contract energy management, alongside its existing pharmaceutical production and wholesale activities [2]. Group 2: Financial Data - As of December 31, 2023, Baoding Tianhao reported total assets of 488.63 million, total liabilities of 319.97 million, and a net asset of 168.66 million, with an annual revenue of 1.21 billion and a net profit of 156.36 million [3]. - For the first nine months of 2024, Baoding Tianhao's total assets were 432.43 million, total liabilities were 288.80 million, net assets were 143.62 million, with a revenue of 906.63 million and a net profit of 131.32 million [3]. - Shaanxi Buchang reported total assets of 3.88 billion, total liabilities of 2.62 billion, and net assets of 1.26 billion as of December 31, 2023, with an annual revenue of 3.34 billion and a net profit of 548.81 million [4]. - As of September 30, 2024, Shaanxi Buchang's total assets were 3.87 billion, total liabilities were 2.98 billion, net assets were 882.65 million, with a revenue of 2.06 billion and a net profit of 254.70 million [4]. Group 3: Authorization and Management - The company has authorized its chairman and president to handle all procedures related to the changes in business scope, including signing relevant documents and submitting government approval applications [4].